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Abstract
Metformin is the main drug of choice for treating type 2 diabetes, yet the therapeutic 
regimens and side effects of the compound are all undesirable and can lead to reduced 
compliance. The aim of this study was to elucidate the mechanism of action of two novel 
compounds which improved glucose handling and weight gain in mice on a high-fat 
diet. Wildtype C57Bl/6 male mice were fed on a high-fat diet and treated with novel, 
anti-diabetic compounds. Both compounds restored the glucose handling ability of these 
mice. At a cellular level, these compounds achieve this by inhibiting complex I activity in 
mitochondria, leading to AMP-activated protein kinase activation and subsequent increased 
glucose uptake by the cells, as measured in the mouse C2C12 muscle cell line. Based on the 
inhibition of NADH dehydrogenase (IC50 27 µmol L−1), one of these compounds is close to a 
thousand fold more potent than metformin. There are no indications of off target effects. 
The compounds have the potential to have a greater anti-diabetic effect at a lower dose 
than metformin and may represent a new anti-diabetic compound class. The mechanism of 
action appears not to be as an insulin sensitizer but rather as an insulin substitute.
Introduction
Whether administered in the early stages of the 
development of type 2 diabetes or as a combination 
therapy with injectables, metformin is the main drug 
of choice for treating the condition. Yet the therapeutic 
regimens, the side effects of the compound, and the 
probable off-target actions are all undesirable and can 
lead to reduced compliance (Donnan et al. 2002, Florez 
et al. 2010, Kirpichnikov et al. 2002). The principal 
mode of action of metformin responsible for its anti-
diabetic effects centers around its role in inhibiting liver 
gluconeogenesis (Bailey & Turner 1996, Madiraju et al. 
2014), antagonising glucagon action (Miller et al. 2013), 
and activating AMP-activated protein kinase (AMPK) 
(Li et al. 2015, Owen et al. 2000). This is achieved via 
either a reduction in the activity of complex I of the 
mitochondrial respiratory chain (Bridges et al. 2014, 
Journal of Molecular 
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Brunmair et al. 2004, El-Mir et al. 2000, Fontaine 2014, 
Owen et al. 2000) or the inhibition of mitochondrial 
glycerophosphate dehydrogenase (Madiraju et al. 2014). 
Other biguanides have similar and more potent effects on 
complex I (Bridges et al. 2014, Matsuzaki and Humphries 
2015), with phenformin dramatically reducing the oxygen 
consumption rate in HepG2 cells (Bridges et al. 2014).
The effect of activating the intracellular metabolic 
sensor, AMPK, is to maintain ATP levels. This is 
achieved via further signaling resulting in an increase 
in glucose uptake by the cell (Pehmøller et al. 2009), 
an increase in fatty acid oxidation (Winder et al. 1997) 
and decrease in fatty acid synthesis (Munday et al. 1988), 
and a decrease in glycogen synthesis (Jørgensen et al. 
2004) and an increase in glycolysis (Marsin et al. 2002). 
AMPK is activated during exercise as the cell seeks to 
replenish levels of ATP (Winder & Hardie 1996). Lowering 
high blood glucose levels in this way would appear to be 
as close to a natural physiological phenomenon as any 
other anti-diabetic mechanism of action.
This study deals with two related, novel compounds 
(PCT/EP2012/071286; see Fig. 1 and Supplementary 
Materials and methods (see section on supplementary 
data given at the end of this article)) with the aim of 
elucidating their mechanism of action. As can be seen, 
their principal mode of action is to inhibit complex I, 
thereby very effectively stimulating AMPK and increasing 
glucose uptake by muscle cells, a major site of insulin 
action within the body. These compounds represent 
a possible new anti-diabetic class and a move away 
from the well-known biguanides. In these respects, 
the compounds activate signaling pathways that are 
influenced in a similar way by exercise (Winder & 
Hardie 1996), and presumably also by metformin. 
Analyses also indicate that these compounds have no 
effects on other anti-diabetic targets and present no 
accepted toxic indicators.
Materials and methods
Animal studies
All procedures were approved by the UK Home Office 
and local ethical committee of the University of Leeds, 
UK. In a prevention study, wildtype C57Bl/6 male 
mice (~20 g; Charles River Laboratories) were housed 
(4 mice per cage) in a conventional animal facility with 
a 12 h light:12 h darkness cycle, given access to water 
and an obesogenic diet ad libitum (Diet F3282; 5450 
kcal kg−1; Bio-serv, Flemington, NJ, USA). Each group 
comprised 8 mice, which were fed for 8 weeks with the 
high-fat diet (HFD) containing DMSO (vehicle control) 
or RTB-70 at 0.04% (w/w) relative to the diet (~1 mg/
mouse/day). In a second series of experiments, mice 
were fed normal chow or the HFD for 16 weeks. The 
mice then underwent a glucose tolerance test which 
indicated that those on the high-fat diet indeed had 
impaired glucose handling abilities (mean AUC values – 
normal chow 17.64 ± 3.7, high-fat diet 36.08 ± 2.9). This 
latter HFD group was then sub-divided (each group had 
8 mice) with one group maintained on the diet and the 
other on the diet plus the addition of RTC-1 at 0.04% 
(w/w) relative to diet (~1 mg/mouse/day), for a further 
16 weeks. At the end of both feeding paradigms, glucose 
(GTT) and insulin tolerance tests (ITT) were carried out. 
Following a period of fasting (12 h and 4 h for GTT and 
ITT, respectively), repeated whole-blood sampling was 
carried out on conscious mice at 30-min intervals after 
an initial i.p. injection of either glucose (1 mg g−1 body 
weight; GTT) or insulin (1 U kg−1 body weight; ITT). 
Body weight was recorded throughout the protocol.
Cell culture
Mouse muscle cells (C2C12; passages 5–25; ECACC 
(STR authenticated)) were differentiated in DMEM 
supplemented with 2% (v/v) horse serum for 3 days. 
RTC-1 and RTB-70 were dissolved in 100% DMSO (to 
50 mmol L−1) and diluted to 1 mmol L−1 in Krebs Ringers 
Buffer (KRB; in mmol L−1: 136 NaCl, 20 HEPES, 4.7 KCl, 
1 MgSO4, 1 CaCl2, 4.05 Na2HPO4, 0.95 NaH2PO4; pH7.4) 
including glucose (5 mmol L−1). The cells were treated 
with RTC-1 or RTB-70 at 10 µmol L−1 in DMEM plus 2% 
(v/v) horse serum overnight or, as indicated, at 37°C. In 
other experiments, C2C12 cells were treated with Insulin 
(100 nmol L−1; 30 min, Sigma), cytochalsin B (10 µmol L−1; 
30 min, Sigma, Flemington, NJ, USA), or metformin 
(500 µmol L−1; 6 h, Sigma). In a further experiment, 
Figure 1
The chemical structures of the potential anti-diabetic compounds 
assessed in this study.
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Compound C (10 µmol L−1; GE Healthcare) was added to the 
cells 1 h before the addition of RTC-1 (10 µmol L−1 for 6 h). 
CHO cells (passages 15 – 25; ECACC) and primary human 
red blood cells were also treated with RTC-1 (10 µmol L−1; 
16 h) before the addition of 3H deoxy-2-glucose.
Glucose uptake
Glucose uptake was monitored using a tritiated version 
of deoxy-2-glucose, a derivative of glucose that cannot be 
metabolized (Yun et al. 2009). Following treatment, the cells 
were washed in KRB and 3H deoxy-2-glucose (1 μCi  mL−1; 
specific activity 8 mCi mmol−1; PerkinElmer) added for 
10 min at 37°C. The cells were washed 3 times in ice-cold 
KRB, solubilized in 0.1% (w/v) SDS for 30 min, and 500 μl 
(~250 μg protein) of the extract added to 2 mL scintillation 
fluid (Ultima Gold, PerkinElmer). The results are expressed 
as counts per minute per mg protein (c.p.m. mg−1; Wallac 
MicroBeta, PerkinElmer) as assayed by the BCA method 
(Smith et al. 1985).
SDS–PAGE and Western immunoblotting
Following drug treatments, the cells were washed in 
PBS and a lysis buffer (in mmol L−1: 50 HEPES (pH 7.5), 
150 NaCl, 10 Na2HPO4, 50 NaF, 1 EDTA, 1.5 MgCl2, 
2 Na3VO4, 1 Na4P2O7, 1 PMSF, 1X SigmaFAST protease 
inhibitor cocktail, 10% (v/v) glycerol, and 1% (v/v) 
Triton X-100) was added. Following incubation for 
1 h, the mixture was centrifuged at 12,000 g and 30 µL 
supernatant were loaded on 12% SDS–PAGE mini 
gels. The proteins were transferred to activated PVDF 
membranes and probed with anti-phospho (Thr172) 
AMPK alpha (diluted 1/1000; Cell Signalling) for 2 h at 
RT. Secondary antibody (anti-rabbit; 1/5000, Dako) was 
added for 1 h at RT. The labeled bands were detected by 
enhanced chemiluminescence.
PPARγ lance assay
The LanthaScreen TR-FRET PPARγ Co-activator Assay 
(Life Technologies) was performed according to the 
manufacturer’s protocol. In an agonist mode, the test 
compounds and agonist control GW1929 (1 µmol L−1; 
Sigma) were incubated with fluorescein-labeled TRAP220/
DRIP-2 coactivator peptide (125 nmol L−1), terbium- 
labeled anti-GST antibody (5 nmol L−1), and PPARγ LBD 
(20 nmol L−1) for 1 h at 25°C. The signals at 520 nm were 
normalized to those obtained from the terbium emission 
at 495 nm, and the 520 nm/495 nm ratios were used as a 
measure for the TRAP220/DRIP-2 coactivator recruitment 
potential of the tested compounds. The ratio of the 
emission intensity of the acceptor (Fluorescein: λ = 520 nm) 
divided by the emission intensity of the donor (Tb: 
λ = 490 nm) was then calculated to determine the degree of 
nuclear receptor coactivator binding. Each measurement 
A B C
D E F
Figure 2
RTB-70 and RTC-1 restore normal glucose handling in high-fat fed mice. Mice fed a high-fat diet and RTB-70 (0.04% (w/w); ∆) for 8 weeks had 
improved glucose handling abilities compared with mice on high-fat diet alone () when assessed by GTT (A) and ITT (B). Mice fed a high-fat diet 
for 16 weeks and then a high-fat diet and RTC-1 () for a further 16 weeks had improved glucose handling abilities compared with mice on 
high-fat diet alone () when assessed by GTT (D) and ITT (E), with levels mimicking control fed mice (●). Total body weights (c-RTB-70 and f-RTC-1) 
are also shown. Bar charts depict area under the curve (AUC) for GTT and ITT, and final body weights. Values are mean ± s.e.m.; n = 8 per group; 
*p < 0.05, **p < 0.01; student’s t-test vs control.
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was performed in duplicate. The 520 nm/495 nm ratio was 
plotted against the test compound concentration.
Homogeneous time-resolved fluorescence (GLP-1R)
The compounds were assayed for GLP-1 activation using 
a HTRF cAMP detection kit (Cisbio, Bedford, MA, USA). 
Briefly, 32,000 hGLP1R-expressing Flp-In HEK293 cells 
were plated in 25 µL/well of PBS with IBMX (Sigma) in 384-
well solid bottom white plates and 15 µL/well compound 
in DMSO solution or controls were added. Following 
30 min incubation at RT, 25 µL/well of labeled d2 cAMP 
and 25 µL/well of anti-cAMP antibody (both diluted 1:20 
in lysis buffer) were added to each well. Signals were 
recorded using the Omega Polarstar (BMG LabTech) with 
excitation at 330 nm and emissions at 615 nm and 660 nm.
Rat liver mitochondria isolation
Rat liver mitochondria were isolated by the method 
described by Chappell and Hansford (1972). Immediately 
after extraction, liver samples were washed free of excess 
blood, trimmed of any fat and connective tissue, finely 
chopped, and placed in 50 mL ice-cold (0–4°C) isolation 
medium (in mmol L−1: 250 sucrose, 5 Tris–HCl, 1 EGTA, pH 
7.4). The tissue was homogenized and centrifuged at 750 g 
for 5 min at 4°C. The supernatant was filtered through a 
sieve before being centrifuged at 12,000 g for 10 min at 
4°C. The resulting mitochondrial pellet was resuspended 
in ice-cold 25 mL isolation medium supplemented with 
2% (w/v) defatted BSA and washed twice by centrifugation 
(12,000 g for 10 min at 4°C). The final mitochondrial pellet 
was resuspended in a small volume of isolation medium, 
and the aliquots were frozen at −20°C.
NADH: ubiquinone oxidoreductase activity analysis
Immediately before the assay, mitochondria were diluted 
in a hypotonic buffer (25 mmol L−1 K2HPO4, 5 mmol L−1 
MgCl2) and permeabilized with three cycles of freeze 
thawing. The assay was carried at 30°C in a 1 mL cuvette 
(Shimadzu UV-2550, Milton Keynes, Buckinghamshire, 
UK). Permeabilized mitochondria were incubated with 
50 mmol L−1 K2HPO4 (pH 7.5), 3 mg mL−1 fatty acid-free BSA, 
300 µmol L−1 KCN and 100 µmol L−1 NADH, and baseline 
activity was measured at 340 nm for 1 min. The reaction was 
initiated with the addition of 60 μmol L−1 ubiquinone and 
the resulting decrease in absorbance was measured for 3 min. 
Varying concentrations of RTC-1 or RTB-70 were then added 
and absorbance was measured for a further 3 min. The effect 
of the compounds on NADH:ubiquinone oxidoreductase 
was determined by comparing activity before and after 
addition, relative to the vehicle control, DMSO. Rotenone 
(1 µmol L−1) was used as a positive control in this assay.
Oxygen consumption of rat liver mitochondria
Oxygen consumption rates were measured by an 
Oxygraph Respirometer (Oroboros, Innsbrück, Austria) 
as previously described (Breen et al. 2006). Mitochondria 
(6.2 µg mL−1) were incubated at 37°C in a respiration 
A
B
C
Figure 3
RTC-1 induces glucose uptake in C2C12 mouse muscle cells. The ability of 
RTC-1 (○) and RTB-70 (∆) to activate the GLP-1R (A) compared with GLP-1 
peptide (), PPARγ (B), and the known agonist GW1929 (1 µmol L−1) was 
assessed. Glucose uptake following RTC-1 and RTB-70 (both 10 µmol L−1; 
16 h) treatment (C) was also assessed, compared with Insulin  
(100 nmol L−1; 30 min). Values are mean ± s.e.m.; n = 6;  
*p < 0.05, ***p < 0.001; student’s t-test vs basal.
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medium (5 mmol L−1 HEPES, 120 mmol L−1 KCl, 
10 mmol L−1 K2HPO4, 1 mmol L−1 EGTA; pH 7.4) to which 
0.1% fatty acid-free bovine serum albumin was added on 
the day of use. Oxygen consumption rates were measured 
as the steady-state rates achieved on addition of glutamate 
(5 mmol L−1) and malate (3 mmol L−1). The sensitivity 
of these steady-state rates to various concentrations of 
RTB-70, RTC-1 or the DMSO vehicle control was then 
determined. Recovery of the steady state was then assessed 
by the addition of 10 mmol L−1 succinate (succinate-
KOH, pH 7.4). The Oroboros Oxygraph Respirometer was 
calibrated according to the procedure of Reynafarje et al. 
(1985), assuming that 406 nmol of oxygen atoms was 
dissolved in 1 mL of ionic incubation medium at 37°C.
ATP assay
The Luminescent ATP Detection Assay (Abcam) was 
performed according to the manufacturer’s instructions. 
C2C12 cells (100 µL) were cultured in a black, clear bottom 
96-well plate, and treated with RTC-1 (10 µmol L−1; 1 and 
2 h) or rotenone (25 µmol L−1; 1 h). The cells were lysed 
by addition of detergent solution (50 µL) and incubated 
for 5 min. Reconstituted substrate buffer (containing 
d-Luciferin and Luciferase; 50 µL) was added to the cells 
and incubated for 15 min before luminescence was 
read. ATP concentration was determined via an ATP 
standard curve.
Cell cytotoxicity assay
Rat hepatocytes were used to test the cytotoxicity of RTC-
1. The cells were plated at 1 × 106 per well and treated with 
each compound for 4 h at 100 µg mL−1. At the end of the 
treatment, a Trypan blue exclusion test was carried out and 
cell viability was assessed using the Countess automated cell 
counter (Life Technologies). The experiments were repeated 
three times and carried out by Pharmidex (London, UK).
A C E
B D F
Figure 4
RTC-1 induces glucose uptake in a specific, time-dependent manner. Dose dependency of RTC-1 (16 h) on glucose uptake in C2C12 cells, with an EC50 
estimated at 11.42 µmol L−1 (dashed line; A). Glucose uptake following RTC-1 (10 µmol L−1; 16 h) treatment of CHO cells (B) and primary erythrocytes (C). 
RTC-1-induced (10 µmol L−1; 16 h) glucose transport inhibited by cytochalasin B (cyto B; 10 µmol L−1; 30 min; D) and co-addition of 5 mmol L−1 ‘cold’ glucose 
(E). The ability of metformin (500 µmol L−1; 16 h) to increase glucose uptake in C2C12 cells compared with RTC-1 (10 µmol L−1; 16 h; F). The values are 
mean ± s.e.m.; n = 4 per group; **p < 0.01, ***p < 0.001; student’s t-test vs basal.
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Effects of RTC-1 on the hERG channel
Effects of RTC-1 on the hERG channel currents were 
determined by the two-electrode voltage clamp technique 
as described previously (Elliott et al. 2009). In brief, cRNA 
was prepared from the hERG cDNA (acc. No. GI:4557729) 
clone in the pSP64 vector using the SP6 Megascript Kit 
(Ambion). Stage V or VI oocytes were isolated from Xenopus 
toads, injected with 50 nL of cRNA (50 pg nL−1), and 
incubated in ND-96 solution (in mmol L−1: 96 NaCl, 2 KCl, 
1.8 CaCl2, 1 MgCl2, 5 HEPES, 2.5 sodium pyruvate, pH 7.5) 
supplemented with 100  μmol L−1 DTT solution at 18°C. 
After 2 – 4 days, currents were recorded in Ringer’s solution 
(in mmol L−1: 115 NaCl, 2 KCl, 1.8 CaCl2, 10 HEPES, pH 7.2) 
using microelectrodes made from borosilicate glass, filled 
with 3 M KCl, which had resistances between 0.5 and 2.0 M. 
The effects of compounds on tail currents at −50 mV were 
examined using a repeated pulse protocol. For this, control 
currents were first measured in Ringer’s solution during 
repeated depolarizing steps (+ 30 mV) delivered from a 
holding potential of −80 mV. The cells were then superfused 
with RTC-1 (10 μmol L−1) and the current recordings 
continued until a steady-state effect was achieved. All 
experiments were repeated at least three times.
Compound synthesis
Details of compound synthesis for this study are given in 
the Supplementary Materials and methods (see section on 
supplementary data given at the end of this article).
Statistical analysis
The values are expressed as the mean ± s.e.m. Statistical 
comparisons are made using two-tailed student’s t-test 
compared with basal levels, unless otherwise stated.
Results
Effects on glucose handling
The initial compound (RTB-70) and one of its derivatives, 
RTC-1, were assessed for their ability to improve glucose 
A
D E F G
B C
Figure 5
RTC-1 induces an increase in AMPK phosphorylation via the inhibition of NADH oxidation. RTC-1-induced (10 µmol L−1) time-dependent increase in the 
phosphorylation of AMPK in C2C12 cells (A). The AMPK inhibitor, Compound C (1 h before addition of RTC-1; 10 µmol L−1), blocks the RTC-1-induced (6 h) 
glucose uptake (B). RTC-1 effect on ATP levels (C). RTC-1- (D) and RTB-70-induced (E) inhibition of oxygen consumption in intact mitochondria. IC50 was 
calculated at 27 µmol L−1 for RTC-1 and 138 µmol L−1 for RTB-70 (indicated by the dashed lines). RTC-1- (F) and RTB-70-induced (G) inhibition of NADH 
oxidation in disrupted mitochondria. IC50 was calculated at 27 µmol L−1 for RTC-1 and 6 µmol L−1 for RTB-70 (indicated by the dashed line). Values are 
mean ± s.e.m.; n = 3 per group; *p < 0.05, ***p < 0.001; student’s t-test vs basal.
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handling in mice subjected to a high-fat diet. In the case of 
RTB-70, the compound was added to the diet for 8 weeks 
from the start of the study. With RTC-1, the compound was 
administered for 16 weeks after a preceding 16 week period 
on the diet alone when insulin resistance became evident. 
Fig. 2A and B reveal that RTB-70 significantly improved 
glucose handling in both glucose and insulin tolerance 
tests. This was also true in the intervention study with 
RTC-1 (Fig. 2D and E). Comparisons with an untreated 
chow-fed group indicated that RTC-1 restored glucose 
handling to levels not significantly different to controls. 
Both compounds also reduced the weight gain exhibited 
by the control groups of animals (Fig. 2C and F). There 
were no significant changes in food intake between the 
control and treated groups. The mice exhibited no adverse 
reaction to the compounds and no hyperactivity was 
observed as well as no deaths occurred.
In order to ascertain the mechanism by which 
these compounds exert their anti-diabetic effects, their 
ability to activate well-known type 2 diabetes targets was 
assessed. Neither RTB-70 nor RTC-1 was agonist of GLP-1R 
(Fig. 3A) or PPARγ (Fig. 3B). The compounds were also 
tested for their effects on glucose uptake in a mouse muscle 
cell line, C2C12. Glucose uptake was assayed by using 
3H-deoxy-2-glucose, a derivative of glucose which cannot 
be metabolized. RTC-1 induced a significant increase 
in glucose uptake compared with vehicle-treated cells 
(Fig. 3C), which was more pronounced than the normal 
response to the positive control, insulin (100 nmol L−1; 
30 min). Perhaps meaningfully, RTB-70 did not affect 
glucose uptake significantly. Furthermore, the derivatives 
of RTC-1 that passed the Eli Lilly ‘Open Innovation Drug 
Discovery’ novelty screen were assessed for their efficacy 
in their anti-diabetic screenings. These compounds did 
not induce the secretion of insulin or GLP-1 from INS-1e 
and NCI cell lines, respectively (data not shown).
RTC-1 induced a concentration-dependent increase 
in glucose uptake when incubated with muscle cells for 
16 h, with an EC50 calculated at ~11 µmol L−1 (Fig. 4A). 
This action of RTC-1 is not restricted to muscle cells as 
treatment of CHO cells with RTC-1 (10 µmol L−1; 16 h) 
also induced a significant increase in glucose uptake 
compared with vehicle-treated controls (Fig. 4B). RTC-1 
is not exerting its effect by directly activating the glucose 
transporter, as no glucose uptake was stimulated in 
erythrocytes (Fig. 4C). However, the ability of cytochalasin 
B (10  µmol L−1; an inhibitor of the glucose transporter) to 
prevent this compound-induced uptake (Fig. 4D) indicated 
that the uptake was facilitated by a glucose transporter. 
This conclusion was reinforced by the observation that 
the addition of excess ‘cold’ glucose (5 mmol L−1) along 
with the 3H deoxy-2-glucose inhibited the amount of 
detectable tritium in the cells (Fig. 4E).
Mechanism of action
AMPK, being the major metabolic biosensor of the cell, 
was the logical protein to investigate. Phosphorylation 
of AMPK at threonine 172 is an indicator of AMPK 
activation. Using C2C12 cells, Western immunoblotting 
A B C
Figure 6
RTC-1 is not cytotoxic and does not activate hERG significantly. Assay of RTC-1 (100 µg/mL; 4 h) cytotoxicity as measured by Trypan Blue exclusion in rat 
hepatocytes compared with the known toxic agents Chlorpromazine and Chloroform (both 100 µg mL−1; A). Representative peak of the effect of RTC-1 
(10 µmol L−1) on tail currents of hERG-expressing oocytes prepared from Xenopus toads, as determined by a repeated pulse protocol (insert:  
representative current traces before (black trace) and after (gray trace) the application of RTC-1; B). Normalized data (n = 3; C), before and after RTC-1 
application. The values are mean ± s.e.m.; n = 3 per group; **p < 0.01, ***p < 0.001; student’s t-test vs control.
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showed that RTC-1 (10 µmol L−1) induced an increase 
in Thr172 phosphorylation of AMPK in a time-
dependent manner, the first increase occurring at 
45 min (Fig. 5A). In order to confirm the sequence of events 
through which glucose enters the cell, pre-treatment 
with an inhibitor of AMPK activation, Compound C (1 h; 
10 µmol L−1), before RTC-1 (10 µmol L−1; 6 h) was seen to 
attenuate the RTC-1-induced increase in glucose uptake 
(Fig. 5B). Therefore indicating that AMPK is a major 
intermediate in the effect of these compounds.
The mode of action of these compounds could be 
a direct effect on the enzyme or through the normal 
biological mechanism, namely an increase in the AMP 
to ATP ratio. RTC-1 induced a decrease (not statistically 
different from basal levels) in ATP levels 1 h after addition 
to cells; there was no discernible difference observed at 2 h 
(Fig. 5C) and thereafter. Rotenone (25 µmol L−1), a 
known complex I inhibitor, acted as a positive control. 
Interestingly, RTC-1 (IC50 27 µmol L−1), and to a lesser 
extent RTB-70 (IC50 138 µmol L−1), both inhibited 
oxygen consumption by mitochondria, (Fig. 5D and 
E, respectively). The addition of succinate restored 
the oxygen consuming ability of these mitochondria 
(Supplementary Fig. 1). These observations led to the 
identification of the target protein. Assays of NADH 
oxidation using purified disrupted mitochondria in 
the presence of ubiquinone indicated that RTC-1 and 
RTB-70 (Fig. 5F and G, respectively) inhibit the NADH 
dehydrogenase in complex I of the electron transport 
chain of mitochondria (IC50 for RTC-1 is 27 µmol L−1). 
The data illustrated in Fig. 4F indicate that metformin, 
which has previously been shown to inhibit complex I 
in muscle cells (Brunmair et al. 2004), has a similar effect 
on glucose uptake in C2C12 mouse muscle cells to that of 
RTC-1. The response is very modest compared with 
RTC-1, despite a 50-fold higher dose.
The cell toxicity profile of RTC-1 confirmed the lack 
of adverse reactions observed in the animal studies. RTC-1 
did not induce cell death in rat hepatocytes following 4 h 
treatment at 100 µg mL−1 compared with the known cyto-
toxic agents chlorpromazine and chloroform (Fig.  6A). 
The ability of druggable compounds to effect hERG, a 
voltage-gated potassium channel involved in cardiac 
action potential repolarization, is a recognized preclinical 
safety test (Bowlby et al. 2008, Priest et al. 2008). RTC-1 
(10 µmol L−1) did not significantly affect hERG tail current 
amplitudes as measured by voltage clamp in oocytes from 
Xenopus toads (Fig. 6B and C).
Discussion
The results above present a potential new class of anti-
diabetic compounds which possess a targeted effect on the 
NADH dehydrogenase of complex I of the mitochondrial 
Figure 7
A proposed mechanism of action of these compounds on muscle cells initially involves the inhibition of the NADH dehydrogenase portion of complex I 
in mitochondria (Step 1). This leads to a build-up of ADP, which is subject to the action of adenylate kinase converting two ADP molecules into one ATP 
and one AMP (Step 2). The rise in AMP levels is detected by AMPK, which is activated by phosphorylation (Step 3). One of the downstream effects of this 
is an increase in glucose uptake via the GLUT4 transporter in the plasma membrane (Step 4). In the whole animal, the action of inducing more glucose 
uptake into the cell not only keeps intracellular ATP at normal levels but importantly reduces circulating glucose levels, thereby reducing the harmful 
effects of glucose intolerance and insulin resistance. A full colour version of this figure is available at http://dx.doi.org/10.1530/JME-15-0225.
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respiratory chain, the result of which is to activate AMPK. 
This enzyme, in turn, activates the pathway by which the 
GLUT4 transporter is mobilized to the plasma membrane 
of most mammalian cells with the consequent increase in 
glucose uptake by the cell. In this respect, the mechanism 
has elements in common with physical exercise (Winder 
& Hardie 1996). In both cases, there is a requirement 
for increased ATP production, probably partly effected 
through an increase in the AMP to ATP ratio through 
the action of adenylate kinase, which is met by elevated 
glucose mobilization/influx and utilization by the cell. 
At the levels studied, cellular ATP levels remain constant, 
though there may be a non-significant transient decrease 
on first exposure of cells to the compounds. This contrasts 
strongly with the effects of rotenone, an insecticide which 
produces long-lasting significant decreases in ATP levels 
(Fendel et al. 2008). These compounds appear to have a 
similar mode of action to metformin (Bridges et al. 2014, 
Brunmair et al. 2004, El-Mir et al. 2000, Fontaine 2014, 
Owen et al. 2000, Zhou et al. 2001), the drug of choice 
for treating type 2 diabetes. Although metformin has 
some major effects on the liver cells (Bailey & Turner 
1996, Madiraju et al. 2014, Miller et al. 2013), it also 
affects xmuscle cells to inhibit complex I activity 
(Brunmair et al. 2004, Wessels et al. 2014), activate 
AMPK (Brunmair et al. 2004, Li et al. 2015, Musi 
et al. 2002) and induce glucose uptake (Kumar & Dey 
2002), which are its other important anti-diabetic 
effects. RTC-1 appears to be more potent in inhibiting 
mictochondrial complex I, with an IC50 calculated at 27 
µmol L−1 compared with previously stated IC50 values 
of between 1.2 and 27 mmol L−1 for metformin (Jenkins 
et al. 2013, Piel et al. 2015). One possible drug-dependent 
side effect of complex I inhibition is reported to be lactic 
acidosis (Brown et al. 1998, Misbin 1977, Wang et al. 
2003). Although this was not specifically tested for in 
these mice, the characteristic symptoms of lactic acidosis, 
such as nausea, vomiting, muscle weakening and rapid 
breathing, were not evident in the mice that were treated 
with the drug for up to 16 weeks. The gastrointestinal 
side effects associated with metformin treatment, such 
as diarrhoea, retching and abdominal pain (Florez et al. 
2010), were also absent. There are no effects on other 
potential drug targets for type 2 diabetes such as the 
GLP-1 receptor and PPARγ. Based on the toxicology 
screenings, there is also no evident toxicity at the 
doses tested.
Studies on mice fed a high-fat diet reflect this 
mechanism of action. Given either at the start of the 
diet or once insulin resistance/type 2 diabetes has been 
established, the compounds effected a very significant 
restoration of the normal GTT and ITT parameters. 
Again there were no indicators of toxicity: no deaths, no 
lethargy or hyperactivity, no diarrhoea, and no change 
in food intake, even on continuous treatment for up to 
16 weeks. The weight gain in the mice was normalized, 
this was particularly evident in the epididymal fat pad 
(C Redondo, personal communication), which was greatly 
increased in the diabetic untreated animals but very 
similar to chow-fed controls in the compound-treated 
groups. The ability of these compounds to improve 
glucose handling in high-fat fed mice is similar to studies 
carried out with metformin (Matsui et al. 2010) and other 
compounds that target complex I (Jenkins et al. 2013).
One unexplained result was the success of RTB-70 
in vivo and in the NADH dehydrogenase assay, as 
measured in disrupted mitochondria (IC50 6.3 µmol L−1), 
but it showed reduced efficacy on the inhibition of 
oxygen consumption as measured in intact mitochondria 
(IC50 138 µmol L−1) and no significant effect on glucose 
uptake as measured in whole cells. These results suggest 
that the compound may not penetrate membrane 
lipids very efficiently and therefore not influence the 
AMP to ATP ratio over the time course of the cellular 
experiments. This inconsistency could, however, be the 
result of the nature and time differences between the 
two kinds of experiment. It may well be that RTB-70 has 
a longer residence time in the animals and is therefore 
able to partition successfully into cells to produce 
similar responses over a time frame of weeks rather 
than hours. There is also the theoretical possibility that 
the compound may be metabolized in vivo to a more 
permeable/active derivative.
All the parameters studied thus far showed that 
these compounds have the potential to have much more 
effective anti-diabetic effect at a very much lower dose 
than metformin. The lower doses may prevent some of 
the intestinal problems associated with the higher doses 
required with metformin treatment (Florez et al. 2010, 
Kirpichnikov et al. 2002); however, both preclinical and 
clinical testing would need to be carried out to confirm 
this. The mechanism of action (schematic: Fig. 7) appears 
not to be as an insulin sensitizer but rather as an insulin 
substitute, and in that respect may also be of value to 
individuals with type 1 diabetes. Since there also promises 
to be a positive effect on weight, that in itself might 
attenuate the deleterious effects of excess visceral adipose 
tissue. It is possible in the future that these compounds 
can become an important tool in the treatment of 
type 2 diabetes.
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